Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Research & Development: 2016-2024

Historic Research & Development for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to $396.4 million.

  • Denali Therapeutics' Research & Development fell 7.44% to $99.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $396.4 million, marking a year-over-year decrease of 6.47%. This contributed to the annual value of $396.4 million for FY2024, which is 6.47% down from last year.
  • As of FY2024, Denali Therapeutics' Research & Development stood at $396.4 million, which was down 6.47% from $423.9 million recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' Research & Development registered a high of $423.9 million during FY2023, and its lowest value of $212.6 million during FY2020.
  • Over the past 3 years, Denali Therapeutics' median Research & Development value was $396.4 million (recorded in 2024), while the average stood at $393.0 million.
  • As far as peak fluctuations go, Denali Therapeutics' Research & Development spiked by 35.19% in 2022, and later declined by 6.47% in 2024.
  • Denali Therapeutics' Research & Development (Yearly) stood at $212.6 million in 2020, then increased by 24.80% to $265.4 million in 2021, then spiked by 35.19% to $358.7 million in 2022, then grew by 18.16% to $423.9 million in 2023, then declined by 6.47% to $396.4 million in 2024.